These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9057806)

  • 21. [Salazosulfapyridine-induced lupus erythematosus syndrome in ulcerative colitis (author's transl)].
    Jaup BH
    Dtsch Med Wochenschr; 1978 Jul; 103(30):1211-3. PubMed ID: 27347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis.
    Kruis W; Brandes JW; Schreiber S; Theuer D; Krakamp B; Schütz E; Otto P; Lorenz-Mayer H; Ewe K; Judmaier G
    Aliment Pharmacol Ther; 1998 Aug; 12(8):707-15. PubMed ID: 9726382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pancreatitis associated with olsalazine and sulfasalazine in children with ulcerative colitis.
    Garau P; Orenstein SR; Neigut DA; Kocoshis SA
    J Pediatr Gastroenterol Nutr; 1994 May; 18(4):481-5. PubMed ID: 7520936
    [No Abstract]   [Full Text] [Related]  

  • 24. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial.
    Meyers S; Sachar DB; Present DH; Janowitz HD
    Gastroenterology; 1987 Dec; 93(6):1255-62. PubMed ID: 2890550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis.
    Zinberg J; Molinas S; Das KM
    Am J Gastroenterol; 1990 May; 85(5):562-6. PubMed ID: 2337059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical tolerance of olsalazine.
    Järnerot G
    Scand J Gastroenterol Suppl; 1988; 148():21-3. PubMed ID: 3067337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
    Stretch GL; Campbell BJ; Dwarakanath AD; Yaqoob M; Stevenson A; Morris AI; Rhodes JM
    Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis.
    Courtney MG; Nunes DP; Bergin CF; O'Driscoll M; Trimble V; Keeling PW; Weir DG
    Lancet; 1992 May; 339(8804):1279-81. PubMed ID: 1349676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group.
    Kiilerich S; Ladefoged K; Rannem T; Ranløv PJ
    Gut; 1992 Feb; 33(2):252-5. PubMed ID: 1347280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of mesalamine and olsalazine in ulcerative colitis.
    Gait JE; Powell JH; Regalli G
    Am Fam Physician; 1993 Nov; 48(7):1234, 1236. PubMed ID: 8237737
    [No Abstract]   [Full Text] [Related]  

  • 31. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine.
    Karamanolis DG; Papatheodoridis GV; Xourgias V
    Eur J Gastroenterol Hepatol; 1996 Nov; 8(11):1083-8. PubMed ID: 8944370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW; Gales BJ
    Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sulphasalazine-induced lupus syndrome in ulcerative colitis.
    Griffiths ID; Kane SP
    Br Med J; 1977 Nov; 2(6096):1188-9. PubMed ID: 22375
    [No Abstract]   [Full Text] [Related]  

  • 34. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.
    Ireland A; Mason CH; Jewell DP
    Gut; 1988 Jun; 29(6):835-7. PubMed ID: 2898422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
    Baker DE; Kane S
    Rev Gastroenterol Disord; 2004; 4(2):86-91. PubMed ID: 15185719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olsalazine--a further choice in ulcerative colitis.
    Drug Ther Bull; 1990 Jul; 28(15):57-8. PubMed ID: 2131213
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy and tolerability of olsalazine (dipentum) in the treatment of patients with ulcerative colitis--results of a field study.
    Singer MV; Schmausser H; Schönfeld G
    Hepatogastroenterology; 2006; 53(69):317-21. PubMed ID: 16795963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial.
    Ferry GD; Kirschner BS; Grand RJ; Issenman RM; Griffiths AM; Vanderhoof JA; Fiedorek SC; Winter HS; Hassall EG; Watkins JB
    J Pediatr Gastroenterol Nutr; 1993 Jul; 17(1):32-8. PubMed ID: 8102399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution of olsalazine.
    Truelove SC
    Scand J Gastroenterol Suppl; 1988; 148():3-6. PubMed ID: 2906475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group.
    Rijk MC; van Lier HJ; van Tongeren JH
    Am J Gastroenterol; 1992 Apr; 87(4):438-42. PubMed ID: 1348159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.